BPC-157 Research Evidence: What Is Published, and How Much Is Human
A source-by-source look at the animal and human literature on BPC-157, who produced most of it, and what recent systematic reviews conclude.
BPC-157, Body Protection Compound 157, is a synthetic 15-amino-acid peptide derived from a gastric protein sequence. A PubMed search on 29 October 2026 for BPC-157 and its alternative spellings returned 237 records. Restricting the search to records with Sikiric as an author returns 176 of them, about 74%, and Seiwerth appears on 164. The literature is large, but it comes overwhelmingly from one research network, which is the most important thing to know before reading any single result.
This article summarises what the studies and recent reviews report. It is a reading guide for researchers, not medical advice.
The animal literature
A 2025 systematic review in HSS Journal looked at the BPC-157 literature from an orthopaedic perspective. From 544 articles published between 1993 and 2024, it included 36 studies: 35 preclinical and 1 clinical. The preclinical studies reported improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bone injury models, along with changes in growth hormone receptor expression and in pathways involved in cell growth and angiogenesis, and reduced inflammatory cytokines.
A 2026 critical review of rodent ischaemia-reperfusion studies found associations with less oxidative injury, modulation of nitric oxide-related vascular responses and lower inflammatory and apoptotic markers, but noted that the evidence is heterogeneous and often relies on short observation periods.
One recent study outside the main network is useful for balance. A 2026 Turkish study randomised 32 rats, eight per group, after Achilles tendon transection and repair to control, BPC-157, TB-500 or both for four weeks. Maximum load to failure was higher in both treated groups than in controls, reaching significance only for TB-500, and the BPC-157 group had numerically better tendon scores that did not reach significance. The combination gave no additional benefit over either agent alone. The authors called it an exploratory study.
Human data
A 2026 PRISMA systematic review found only three human studies of BPC-157, with 30 participants in all: a retrospective study of intra-articular injections for knee pain (16 people), a retrospective pilot of intravesical use for interstitial cystitis (12), and a prospective pilot of intravenous safety (2). Most participants reported symptom improvement and no treatment-related adverse events, but the studies were of poor methodological quality and the certainty of evidence was rated very low. The authors concluded that BPC-157 should not be used clinically in humans outside ethically approved, regulated, high-quality trials.
Two further 2026 reviews, in the American Journal of Sports Medicine and the Journal of the American Academy of Orthopaedic Surgeons, reached the same position. Human musculoskeletal evidence amounts to one small, uncontrolled retrospective case series without validated outcome measures, and validated dosing, pharmacokinetic and long-term safety data are lacking. The orthopaedic review also raised product-quality concerns about the identity, purity, concentration and sterility of commercial preparations.
Regulatory and sporting status
The HSS Journal review notes that BPC-157 lacks US Food and Drug Administration approval and that its use is banned in professional sports. A 2026 review of peptides in sports medicine describes BPC-157 and similar compounds as part of a gray market of unapproved agents operating largely outside regulatory oversight.
How to read this literature
The preclinical record is broad and mostly positive, but it is concentrated in one group's work, uses varied models and doses, and has limited independent replication. The human record is three small, low-quality studies. BPC-157 is accordingly a research compound with a plausible preclinical profile and no established clinical evidence.
QSC supplies BPC-157 in 5 mg, 10 mg and 20 mg vials strictly for laboratory research. It is not approved for human or veterinary use, and nothing here is a dosing recommendation. See also our overview of how BPC-157 and TB-500 are studied together, and the article on what TB-500 actually is.
Sources
Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal, 2025;21(4):485-495. doi:10.1177/15563316251355551. PMID 40756949.
Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthopaedica Belgica, 2026;92(3). doi:10.52628/92.3.15837. PMID 42885452.
Demirtas H et al. BPC 157 in rodent ischemia-reperfusion injury: a critical review of preclinical evidence. International Journal of Molecular Sciences, 2026;27(18):8344. doi:10.3390/ijms27188344. PMID 42794771.
Bicer O et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Joint Diseases and Related Surgery, 2026;37(3):822-837. doi:10.52312/jdrs.2026.2951. PMID 42542926.
Mayfield CK et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. American Journal of Sports Medicine, 2026;54(1):223-229. doi:10.1177/03635465251357593. PMID 41476424. Tham A et al. Investigational peptides in orthopaedic practice: evidence, safety, and patient counseling for BPC-157, thymosin beta-4 and TB-500. Journal of the American Academy of Orthopaedic Surgeons, 2026 (online ahead of print, 27 October 2026). doi:10.5435/JAAOS-D-26-00049. PMID 42937313.
Mendias CL et al. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Medicine, 2026;56(8):1921-1935. doi:10.1007/s40279-026-02437-0. PMID 41966639.
PubMed record counts: query ("BPC 157" OR "BPC-157" OR "body protection compound"), and the same query AND Sikiric[Author] or Seiwerth[Author], run 29 October 2026.
